References
Grigg A, Solal-celigny P, Hoskin P et al (2003) Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 44:1503–1508. https://doi.org/10.1080/1042819031000103953
Sasaki K, Miyauchi M, Ogura M, Shimura-Nukina A, Toyama K, Nakazaki K, Watadani T, Abe O, Kurokawa M (2019) Arteritis after administration of granulocyte colony-stimulating factor: a case series. Int J Hematol. 110:370–374. https://doi.org/10.1007/s12185-019-02662-6
Sato Y, Kaji S, Ueda H, Tomii K (2017) Thoracic aortitis and aortic dissection following pegfilgrastim administration. Eur J Cardio-thoracic Surg 52:993–994. https://doi.org/10.1093/ejcts/ezx165
Parodis I, Dani L, Notarnicola A, Martenhed G, Fernström P, Matikas A, Wiklander OPB (2019) G-CSF-induced aortitis: two cases and review of the literature. Autoimmun Rev 18:615–620. https://doi.org/10.1016/j.autrev.2018.12.011
Hoshina H, Takei H (2019) Granulocyte-colony stimulating factor-associated aortitis in a woman with advanced breast cancer: a case report and review of the literature. BMC Cancer 19. https://doi.org/10.1186/s12885-019-6403-9
Hiranuma K, Kusunoki S, Fujino K, Hirayama T, Ota T, Terao Y (2018) Drug-induced aortitis in a patient with ovarian cancer treated with bevacizumab combination therapy. Taiwan J Obstet Gynecol 57:750–752. https://doi.org/10.1016/j.tjog.2018.08.026
Fiegl M, Steger GG, Studnicka M, Eisterer W, Jaeger C, Willenbacher W (2013) Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study. Curr Med Res Opin 29:505–515. https://doi.org/10.1185/03007995.2013.781018
Oshima Y, Takahashi S, Tani K, Tojo A (2019) Granulocyte colony-stimulating factor-associated aortitis in the Japanese Adverse Drug Event Report database. Cytokine 119:47–51. https://doi.org/10.1016/j.cyto.2019.02.013
Miller EB, Grosu R, Landau Z (2016) Isolated abdominal aortitis following administration of granulocyte colony stimulating factor (G-CSF). Clin Rheumatol 35:1655–1657. https://doi.org/10.1007/s10067-016-3253-6
Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266. https://doi.org/10.1002/cncr.21847
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval and informed consent
Informed consent was obtained from the patient for inclusion in this study.
Conflict of interest
Mineo Kurokawa: Dr. Kurokawa reports grants from Astellas Pharma, grants from Kyowa Kirin Co., Ltd.; grants from Takeda Pharmaceutical Company Limited.; grants from Ono Pharmaceutical CO., Ltd.; grants from Nippon Shinyaku Co., Ltd.; and grants from Novartis Pharmaceuticals, outside the submitted work. Kensuke Matsuda: Dr. Matsuda received a lecture fee from Kyowa Kirin. The other authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sasaki, K., Matsuda, K., Miyauchi, M. et al. A retrospective analysis on arteritis after administration of granulocyte colony-stimulating factor. Ann Hematol 100, 1341–1343 (2021). https://doi.org/10.1007/s00277-021-04453-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-021-04453-8